THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Eli Lilly's Strattera approved for ADHD maintenance in kids

Email|Print|Single Page| Text size – +
May 8, 2008

INDIANAPOLIS—Eli Lilly and Co. said Thursday the Food and Drug Administration approved its drug Strattera for maintenance of attention-deficit/hyperactivity disorder in children and adolescents.

The company said Strattera is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults. Stimulant drugs currently on the market include Shire Pharmaceuticals' Adderall and Novartis' Ritalin.

ADHD is one of the most common mental health disorders in children and adolescents. Lilly said long-term studies showed Strattera provides uninterrupted relief from ADHD symptoms beyond the school day into the evening.

Lilly did note that Strattera has been shown to increase the risk of suicidal thoughts in some children and teens, with a combined analysis of 12 studies showing the risk was 0.4 percent compared with none for those taking a sugar pill. A similar analysis in adults treated with Strattera did not reveal increased risk of suicidal thoughts.

© Copyright 2008 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

more stories like this

  • Email
  • Email
  • Print
  • Print
  • Single page
  • Single page
  • Reprints
  • Reprints
  • Share
  • Share
  • Comment
  • Comment
 
  • Share on DiggShare on Digg
  • Tag with Del.icio.us Save this article
  • powered by Del.icio.us
Your Name Your e-mail address (for return address purposes) E-mail address of recipients (separate multiple addresses with commas) Name and both e-mail fields are required.
Message (optional)
Disclaimer: Boston.com does not share this information or keep it permanently, as it is for the sole purpose of sending this one time e-mail.